Advanced Search
Search Results
6557 total results found
46 - Clinical relevance14,15
Clinical relevance14,15
47 - Who is at risk10,1416,18
Who is at risk?10,14–16,18
48 - How to avoid1416,18
How to avoid14–16,18 Depression and anxiety disorders CHAPTER 3 Clinical relevance14,15 The symptoms of a withdrawal reaction may be mistaken for a relapse of illness or the emergence of a new physical illness,16 leading to unnecessary investigations or reintr...
49 - How to treat1416,23
How to treat14–16,23
50 - References
References 376 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 3 difficult to stop.13 At-risk patients (see above) may need a slower taper. Agomelatine can probably be stopped abruptly without provoking withdrawal symptoms but should be slowly with...
51 - Stopping antidepressants
Stopping antidepressants
52 - Rate of tapering
Rate of tapering 378 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 3 Stopping antidepressants Up to 50% of patients will experience withdrawal symptoms on reducing or stopping an antidepressant,1,2 but symptoms are less common in shorter-term use...
53 - Pattern of tapering
Pattern of tapering Depression and anxiety disorders CHAPTER 3 Pattern of tapering Although reducing by linear amounts (e.g. 50mg, 37.5mg, 25mg, 12.5mg, 0 for sertraline) seems intuitively reasonable (and practical, through splitting tablets), because of the h...
54 - Practical application of tapering
Practical application of tapering 380 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 3 Practical application of tapering Before tapering All patients should be informed of the risk of withdrawal symptoms on stopping any antidepressant. Some antidep...
55 - Troubleshooting
Troubleshooting Depression and anxiety disorders CHAPTER 3 A cautious initial rate of reduction is prudent. The rate of withdrawal can be sped up if symptoms are tolerable. If severe withdrawal symptoms are precipitated by the first step down, then the process...
56 - References
References 382 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 3 Unfortunately, most current tablet formulations of antidepressants do not permit hyperbolic tapering regimens, so patients will require the use of liquid formulations, as recommended b...
57 - Electroconvulsive therapy and psychotropic dr
Electroconvulsive therapy and psychotropic drugs 384 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 3 Electroconvulsive therapy and psychotropic drugs Psychotropics are often continued during ECT. Some agents, such as antidepressants,1,2 enhance it...
58 - References
References 386 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 3 References Pluijms EM, et al. Influence of an adjuvant antidepressant on the efficacy of electroconvulsive therapy: a systematic review and meta-analysis. Aust N Z J Psychiatry 2021;...
59 - Psychostimulants in depression
Psychostimulants in depression 388 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 3 Psychostimulants in depression Psychostimulants reduce fatigue, promote wakefulness and can be mood elevating. Amfetamines have been used as treatments for depressi...
60 - References
References Depression and anxiety disorders CHAPTER 3 References Satel SL, et al. Stimulants in the treatment of depression: a critical overview. J Clin Psychiatry 1989; 50:241–249. Warneke L. Psychostimulants in psychiatry. Can J Psychiatry 1990; 35:3–10. Go...
61 - Post stroke depression
Post-stroke depression
62 - Prophylaxis of post stroke depression
Prophylaxis of post-stroke depression
63 - Treatment of post stroke depression
Treatment of post-stroke depression Depression and anxiety disorders CHAPTER 3 Post-stroke depression Depression is a well-established risk factor for stroke.1,2 In addition, depression is seen in at least 30–40% of survivors of stroke3,4 and post-stroke de...